Business Context and Reporting Period
This Form 8-K, dated June 8, 2021, reports on the extraordinary general meeting of ARYA Sciences Acquisition Corp III ("ARYA"). The filing details the shareholder vote results regarding a proposed business combination with Nautilus Biotechnology, Inc. ("Nautilus"). The report covers the voting event held on June 8, 2021, and the anticipated consummation of the transaction on June 9, 2021.
Key Financial Metrics
This filing is a current report regarding corporate governance and transaction approval; it does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for either ARYA or Nautilus. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Voting Results
Shareholders approved all proposals necessary to proceed with the business combination. A total of 14,520,657 ordinary shares were present, representing 75.68% of the voting power. The specific voting results were as follows:
- Business Combination Proposal: 14,260,138 For; 259,510 Against; 1,009 Abstain.
- Domestication Proposal: 14,258,975 For; 259,863 Against; 1,819 Abstain.
- Charter Proposal: 14,259,527 For; 259,386 Against; 1,744 Abstain.
- Nasdaq Proposal: 14,257,947 For; 260,356 Against; 2,354 Abstain.
- Employee Stock Purchase Plan Proposal: 14,251,808 For; 265,454 Against; 3,395 Abstain.
- Advisory Governing Documents Proposals (A-D) and Incentive Award Plan: All received majority approval, though with higher "Against" vote counts compared to the core transaction proposals.
Due to the approval of all proposals, the "Adjournment Proposal" was not presented to shareholders.
Outlook, Management Commentary, and Risks
Following the shareholder approval, the transactions are expected to be consummated on June 9, 2021, subject to the satisfaction or waiver of closing conditions. Upon completion, the combined company ("New Nautilus") is expected to begin trading on the Nasdaq Capital Market under the symbol "NAUT" on June 10, 2021.
The filing includes extensive forward-looking statements and risk disclosures. Key risks identified include:
- Failure to consummate the business combination or termination of the agreement.
- Disruption of current plans and operations during integration.
- Inability to realize anticipated benefits or grow profitably.
- Retention of key employees.
- Volume of redemption requests by ARYA shareholders.
- Failure to maintain Nasdaq listing post-acquisition.
Investor Verification Checklist
- Verify the final closing date of the transaction (expected June 9, 2021) and any conditions precedent that may delay consummation.
- Confirm the commencement of trading for the new ticker symbol "NAUT" on the Nasdaq Capital Market on June 10, 2021.
- Review the definitive Proxy Statement filed on May 14, 2021, for detailed terms of the Business Combination Agreement and financial projections.
- Monitor for any unsolicited offers or legal proceedings that could interfere with the transaction.
- Assess the impact of shareholder redemptions on the post-transaction capital structure.